Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2023-12-22 00:00:00 ET · period of report 2023-12-22 · accession 0000950170-23-072763 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-22 | 2023-12-22 | SYRE | Burrows Scott L | CFO | A - Grant | $0.00 | +135.0K | 135.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-22 | A | A | 134,953 | $0.00 | 134,953 | D | — | — | (F1) Represents 134,953 restricted stock units ("RSUs") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer. |